Get the Stockscreener App
139.31
0.14%
0.19
Biogen Inc stock is traded at $139.31, with a volume of 1.20M.
It is up +0.14% in the last 24 hours and up +8.96% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$139.12
Open:
$140.41
24h Volume:
1.20M
Relative Volume:
0.84
Market Cap:
$20.42B
Revenue:
$9.61B
Net Income/Loss:
$1.53B
P/E Ratio:
13.32
EPS:
10.46
Net Cash Flow:
$1.85B
1W Performance:
+0.51%
1M Performance:
+8.96%
6M Performance:
-0.95%
1Y Performance:
-31.48%
1-Day Range:
$138.65
$142.32
1-Week Range:
$135.74
$142.32
52-Week Range:
$110.03
$206.70
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
139.31 | 19.93B | 9.61B | 1.53B | 1.85B | 10.46 |
|
LLY
Lilly Eli Co
|
711.68 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
179.29 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
210.60 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.98 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
87.37 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen’s Phase 3 Study on Felzartamab: A Potential Game-Changer for IgA Nephropathy - TipRanks
Biogen’s Innovative Litifilimab Study: A Potential Game-Changer in Drug Delivery - TipRanks
Stock Analysis | Biogen OutlookA Bearish Outlook Amid Mixed Fundamentals and Analyst Disagreement - AInvest
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 25,875 Shares of Biogen Inc. $BIIB - MarketBeat
Aberdeen Group plc Sells 396,597 Shares of Biogen Inc. $BIIB - MarketBeat
From Medford to Harvard: How a summer program shaped Eleanor Nkera's scientific journey - The Business Journals
Tocqueville Asset Management L.P. Sells 17,160 Shares of Biogen Inc. $BIIB - MarketBeat
Marathon Trading Investment Management LLC Sells 11,783 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Position Increased by Neuberger Berman Group LLC - MarketBeat
Cognitive Impairment Associated with Schizophrenia Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | CAutifony Therapeutics, Cyclerion Therapeutics, Biogen - Barchart.com
Fjarde AP Fonden Fourth Swedish National Pension Fund Cuts Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Zacks Research Brokers Lower Earnings Estimates for Biogen - MarketBeat
Evaluating Biogen’s Prospects After Recent FDA Approval Boosts Shares by 6% - simplywall.st
Resona Asset Management Co. Ltd. Purchases 2,104 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen's 1.94% Decline Amid 389th Trading Volume Rank as Institutions Double Down and Analysts Clash on Price Targets - AInvest
Europe Biosimilars Market Analysis: Key Players & Market Share | - openPR.com
Sprucegrove Investment Management Ltd. Has $1.93 Million Holdings in Biogen Inc. $BIIB - MarketBeat
National Pension Service Raises Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Russell Investments Group Ltd. Has $28.44 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Gulf International Bank UK Ltd Sells 3,399 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. shares rise 2.07% premarket as global markets remain muted. - AInvest
E Fund Management Co. Ltd. Purchases 3,160 Shares of Biogen Inc. $BIIB - MarketBeat
Wealthedge Investment Advisors LLC Has $530,000 Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Sector Gamma AS Has $2.55 Million Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Fox Run Management L.L.C. Invests $1.25 Million in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
4,846 Shares in Biogen Inc. (NASDAQ:BIIB) Bought by AIA Group Ltd - MarketBeat
Biogen announces trial win for higher Spinraza doze - MSN
Roche Holding AG: Navigating Patent Expirations and Innovation in a Competitive Pharma Landscape - AInvest
Recent Uptick Might Appease Biogen Inc. (NASDAQ:BIIB) Institutional Owners After Losing 31% Over the Past Year - 富途牛牛
Why Biogen Inc. stock is on top investor watchlistsPortfolio Value Summary & Weekly Hot Stock Watchlists - beatles.ru
Biogen Stock Is Mutating Into a Value Play - MSN
Biogen’s New Clinical Trial: A Potential Game-Changer for Kidney Transplant Patients - MSN
Inspire Trust Co. N.A. Purchases 2,000 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen’s Felzartamab Study: A Potential Game-Changer for IgA Nephropathy - MSN
LPL Financial LLC Purchases 18,183 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wolfe Research Forecasts Biogen's Q4 Earnings (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Stock Holdings Trimmed by Entropy Technologies LP - MarketBeat
Mizuho Securities USA LLC Sells 2,091 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Forsta AP Fonden - MarketBeat
Biogen Shares Surge 2.71% on $230M Volume Boosted by Pipeline Progress Ranks 444th in Market Activity - AInvest
Biogen’s Omaveloxolone Study: A New Hope for Young FA Patients - TipRanks
Biogen’s Litifilimab Study: A Long-Term Look at Lupus Treatment - TipRanks
Biogen (BIIB) Price Target Hiked to $130 at UBS amid Leqembi Development - MSN
National Bank of Canada FI Acquires 23,644 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Deutsche Bank AG Cuts Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
White Lighthouse Investment Management Inc. Purchases New Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Charles Schwab Investment Management Inc. Raises Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Position Raised by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
April 2026 Options Now Available For Biogen (BIIB) - Nasdaq
Piper Sandler raises Biogen stock price target to $118 on Alzheimer’s drug data By Investing.com - Investing.com South Africa
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.46%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):